Skip to content

Alto Neuroscience ANRO Restricted Cash

Restricted Cash at other companies

Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$7.85M-10.5%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$105K0.0%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$2.22M+6.2%
LBR
LB Pharmaceuticals Inc Common StockLBRX
$776K
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
$207K
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX

Other financials

Income statement

See full
Operating income-$27.1M-73.1%
Net income-$26.2M-73.0%
EPS (diluted)-$0.80-42.9%

Balance sheet

See full
Cash & equivalents$264.3M+63.9%
Total debt$20.9M-17.2%
Total equity$243.4M+75.0%
Total assets$276.3M+60.7%

Cash flow

See full
Operating cash flow-$27.1M-63.6%
CapEx$556.0K+2,217%
Free cash flow-$27.6M-66.7%

Valuation

See full
Market cap$887.88M+1,358%
Enterprise value$644.49M-958%

Returns & leverage

See full
Return on equity-38.9%+0.9pp
Debt / equity0.1×-0.1×
Current ratio20.5×-2.0×

Where this comes from

Reported directly by Alto Neuroscience in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alto Neuroscience's restricted cash?
Alto Neuroscience (ANRO) reported restricted cash of $500K in Q1 2026.
How has Alto Neuroscience's restricted cash changed year-over-year?
Alto Neuroscience's restricted cash decreased by 0.0% year-over-year, from $500K to $500K.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.